Skip to content

Short-term Use of Remifentanil during Endotracheal Extubation for Prophylactic Analgesia in Neurosurgical Patients after Craniotomy: a Randomized Controlled Trial. (SURE after Craniotomy Study)

Short-term Use of Remifentanil during Endotracheal Extubation for Prophylactic Analgesia in Neurosurgical Patients after Craniotomy: a Randomized Controlled Trial. (SURE after Craniotomy Study)

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-PRC-13003879
Enrollment
Unknown
Registered
2013-11-18
Start date
2014-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients after craniotomy

Interventions

Remifentenil group:Remifentenil bolus of 0.5ug/kg
Normal saline group:0.9% NS

Sponsors

Department of Critical Care Medicine, Beijing Tiantan Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with delayed extubation after craniotomy admitted to the ICU: 1. Aged 18-65 years old; 2. Consciousness and can cooperate to complete the visual analogue scale evaluation; 3. Comply with standard of extubion evaluated by neurosurgeon and ICU physician, and ready to be extubated.

Exclusion criteria

Exclusion criteria: Exclusion criteria are: 1. Operation related to medulla oblongata area; 2. Liver insufficiency; 3. Renal insufficiency; 4. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Percentage of patients with severe pain during extubation;

Secondary

MeasureTime frame
VAS during extubation;Percentage of patients failed to pass extubation;Respiratory rate/heart rate/blood pressure/pulse, Blood oxygen saturation;Reintubation at 24 hours and 72 hours after Extubation;Percentage of patients with re-operation due to Intracranial hemorrhage or edema;Percentage of patients with severe side effect after giving medicine;Length of stay in ICU and hospital;

Countries

China

Contacts

Public ContactJianxin Zhou

Department of Critical Care Medicine, Beijing Tiantan Hospital Affiliated to Capital Medical University

zhoujx.cn@gmail.com+86 13801183875

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 7, 2026